CA2473814A1 - Methode et marqueurs de diagnostic des maladies renales - Google Patents

Methode et marqueurs de diagnostic des maladies renales Download PDF

Info

Publication number: CA2473814A1
Authority: CA; Canada
Prior art keywords: marker; polypeptide; diabetes; disease; probability
Prior art date: 2004-07-13
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA 2473814

Other languages

English (en)

Inventor

Harald Mischak

Thorsten Kaiser

Stefan Wittke

Michael Walden

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Mosaiques Diagnostics and Therapeutics AG

Original Assignee

Mosaiques Diagnostics and Therapeutics AG

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-07-13

Filing date

2004-07-13

Publication date

2006-01-13

2004-07-13 Application filed by Mosaiques Diagnostics and Therapeutics AG filed Critical Mosaiques Diagnostics and Therapeutics AG

2004-07-13 Priority to CA 2473814 priority Critical patent/CA2473814A1/fr

2006-01-13 Publication of CA2473814A1 publication Critical patent/CA2473814A1/fr

Status Abandoned legal-status Critical Current

Links

238000000034 method Methods 0.000 title claims abstract description 60
208000017169 kidney disease Diseases 0.000 title claims abstract description 47
238000003745 diagnosis Methods 0.000 title claims abstract description 38
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 163
102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 156
229920001184 polypeptide Polymers 0.000 claims abstract description 150
239000003550 marker Substances 0.000 claims abstract description 64
201000010099 disease Diseases 0.000 claims abstract description 61
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 61
238000003748 differential diagnosis Methods 0.000 claims abstract description 34
210000002700 urine Anatomy 0.000 claims abstract description 31
208000010159 IgA glomerulonephritis Diseases 0.000 claims abstract description 30
206010021263 IgA nephropathy Diseases 0.000 claims abstract description 30
208000007342 Diabetic Nephropathies Diseases 0.000 claims abstract description 15
208000033679 diabetic kidney disease Diseases 0.000 claims abstract description 14
201000005206 focal segmental glomerulosclerosis Diseases 0.000 claims description 59
238000005251 capillar electrophoresis Methods 0.000 claims description 27
238000000738 capillary electrophoresis-mass spectrometry Methods 0.000 claims description 23
238000004949 mass spectrometry Methods 0.000 claims description 19
238000001502 gel electrophoresis Methods 0.000 claims description 5
238000005259 measurement Methods 0.000 claims description 5
238000001262 western blot Methods 0.000 claims description 4
238000002965 ELISA Methods 0.000 claims description 3
238000003127 radioimmunoassay Methods 0.000 claims description 3
238000001616 ion spectroscopy Methods 0.000 claims description 2
238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims description 2
238000000338 in vitro Methods 0.000 claims 1
206010018374 Glomerulonephritis minimal lesion Diseases 0.000 abstract description 65
208000004883 Lipoid Nephrosis Diseases 0.000 abstract description 65
201000008350 membranous glomerulonephritis Diseases 0.000 abstract description 6
206010061989 glomerulosclerosis Diseases 0.000 abstract 1
206010012601 diabetes mellitus Diseases 0.000 description 157
231100000854 focal segmental glomerulosclerosis Toxicity 0.000 description 54
239000000523 sample Substances 0.000 description 49
239000003446 ligand Substances 0.000 description 40
108090000623 proteins and genes Proteins 0.000 description 34
102000004169 proteins and genes Human genes 0.000 description 32
238000004458 analytical method Methods 0.000 description 17
238000003491 array Methods 0.000 description 17
230000027455 binding Effects 0.000 description 13
239000012634 fragment Substances 0.000 description 12
238000013508 migration Methods 0.000 description 12
241000282414 Homo sapiens Species 0.000 description 11
150000001413 amino acids Chemical class 0.000 description 11
230000005012 migration Effects 0.000 description 11
238000012706 support-vector machine Methods 0.000 description 9
230000002485 urinary effect Effects 0.000 description 9
208000022461 Glomerular disease Diseases 0.000 description 8
238000001514 detection method Methods 0.000 description 8
238000003795 desorption Methods 0.000 description 7
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
239000002253 acid Substances 0.000 description 6
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
102000039446 nucleic acids Human genes 0.000 description 6
150000007523 nucleic acids Chemical class 0.000 description 6
230000035945 sensitivity Effects 0.000 description 6
238000000926 separation method Methods 0.000 description 6
239000012491 analyte Substances 0.000 description 5
238000002790 cross-validation Methods 0.000 description 5
238000000132 electrospray ionisation Methods 0.000 description 5
230000036541 health Effects 0.000 description 5
150000002500 ions Chemical class 0.000 description 5
108020004707 nucleic acids Proteins 0.000 description 5
238000007637 random forest analysis Methods 0.000 description 5
239000000126 substance Substances 0.000 description 5
239000000758 substrate Substances 0.000 description 5
238000002560 therapeutic procedure Methods 0.000 description 5
238000001419 two-dimensional polyacrylamide gel electrophoresis Methods 0.000 description 5
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
108091023037 Aptamer Proteins 0.000 description 4
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 4
238000000502 dialysis Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
238000002347 injection Methods 0.000 description 4
238000002372 labelling Methods 0.000 description 4
238000007619 statistical method Methods 0.000 description 4
239000000725 suspension Substances 0.000 description 4
230000007704 transition Effects 0.000 description 4
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
239000005541 ACE inhibitor Substances 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 3
229930105110 Cyclosporin A Natural products 0.000 description 3
108010036949 Cyclosporine Proteins 0.000 description 3
206010029164 Nephrotic syndrome Diseases 0.000 description 3
FYKUEXMZYFIZKA-DCAQKATOSA-N Pro-Pro-Gln Chemical compound [H]N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(O)=O FYKUEXMZYFIZKA-DCAQKATOSA-N 0.000 description 3
208000001647 Renal Insufficiency Diseases 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
-1 acridan ester Chemical class 0.000 description 3
229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 3
230000008901 benefit Effects 0.000 description 3
238000001574 biopsy Methods 0.000 description 3
229960002685 biotin Drugs 0.000 description 3
239000011616 biotin Substances 0.000 description 3
229960001265 ciclosporin Drugs 0.000 description 3
230000008878 coupling Effects 0.000 description 3
238000010168 coupling process Methods 0.000 description 3
238000005859 coupling reaction Methods 0.000 description 3
229960004397 cyclophosphamide Drugs 0.000 description 3
239000007857 degradation product Substances 0.000 description 3
235000019253 formic acid Nutrition 0.000 description 3
230000014509 gene expression Effects 0.000 description 3
239000003862 glucocorticoid Substances 0.000 description 3
201000006370 kidney failure Diseases 0.000 description 3
238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 3
239000011159 matrix material Substances 0.000 description 3
239000012528 membrane Substances 0.000 description 3
230000000750 progressive effect Effects 0.000 description 3
239000007790 solid phase Substances 0.000 description 3
229940037128 systemic glucocorticoids Drugs 0.000 description 3
238000001269 time-of-flight mass spectrometry Methods 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
108010088751 Albumins Proteins 0.000 description 2
102000009027 Albumins Human genes 0.000 description 2
CELPEWWLSXMVPH-CIUDSAMLSA-N Asp-Asp-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC(O)=O CELPEWWLSXMVPH-CIUDSAMLSA-N 0.000 description 2
BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
KRGZZKWSBGPLKL-IUCAKERBSA-N Glu-Gly-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)N KRGZZKWSBGPLKL-IUCAKERBSA-N 0.000 description 2
LWYUQLZOIORFFJ-XKBZYTNZSA-N Glu-Thr-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CCC(=O)O)N)O LWYUQLZOIORFFJ-XKBZYTNZSA-N 0.000 description 2
102000008100 Human Serum Albumin Human genes 0.000 description 2
108091006905 Human Serum Albumin Proteins 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
CYZBFPYMSJGBRL-DRZSPHRISA-N Phe-Ala-Glu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O CYZBFPYMSJGBRL-DRZSPHRISA-N 0.000 description 2
BPIMVBKDLSBKIJ-FCLVOEFKSA-N Phe-Thr-Phe Chemical compound C([C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 BPIMVBKDLSBKIJ-FCLVOEFKSA-N 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
108010026552 Proteome Proteins 0.000 description 2
102000004142 Trypsin Human genes 0.000 description 2
108090000631 Trypsin Proteins 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
238000001042 affinity chromatography Methods 0.000 description 2
238000013459 approach Methods 0.000 description 2
235000020958 biotin Nutrition 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
239000007795 chemical reaction product Substances 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
238000004891 communication Methods 0.000 description 2
108010004073 cysteinylcysteine Proteins 0.000 description 2
239000003814 drug Substances 0.000 description 2
238000013399 early diagnosis Methods 0.000 description 2
238000001962 electrophoresis Methods 0.000 description 2
238000000605 extraction Methods 0.000 description 2
239000012530 fluid Substances 0.000 description 2
239000011521 glass Substances 0.000 description 2
230000013595 glycosylation Effects 0.000 description 2
238000006206 glycosylation reaction Methods 0.000 description 2
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
239000010931 gold Substances 0.000 description 2
229910052737 gold Inorganic materials 0.000 description 2
230000002209 hydrophobic effect Effects 0.000 description 2
238000001597 immobilized metal affinity chromatography Methods 0.000 description 2
238000003018 immunoassay Methods 0.000 description 2
238000005040 ion trap Methods 0.000 description 2
238000000050 ionisation spectroscopy Methods 0.000 description 2
230000000155 isotopic effect Effects 0.000 description 2
239000004816 latex Substances 0.000 description 2
229920000126 latex Polymers 0.000 description 2
239000007788 liquid Substances 0.000 description 2
238000011068 loading method Methods 0.000 description 2
230000005291 magnetic effect Effects 0.000 description 2
230000014759 maintenance of location Effects 0.000 description 2
239000011325 microbead Substances 0.000 description 2
239000004005 microsphere Substances 0.000 description 2
238000004848 nephelometry Methods 0.000 description 2
201000008383 nephritis Diseases 0.000 description 2
239000012071 phase Substances 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
238000004393 prognosis Methods 0.000 description 2
230000002285 radioactive effect Effects 0.000 description 2
238000002821 scintillation proximity assay Methods 0.000 description 2
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
239000002904 solvent Substances 0.000 description 2
238000001228 spectrum Methods 0.000 description 2
238000012360 testing method Methods 0.000 description 2
239000012588 trypsin Substances 0.000 description 2
238000004879 turbidimetry Methods 0.000 description 2
OBHRVMZSZIDDEK-UHFFFAOYSA-N urobilinogen Chemical compound CCC1=C(C)C(=O)NC1CC1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(CC3C(=C(CC)C(=O)N3)C)N2)CCC(O)=O)N1 OBHRVMZSZIDDEK-UHFFFAOYSA-N 0.000 description 2
238000005406 washing Methods 0.000 description 2
AUXMWYRZQPIXCC-KNIFDHDWSA-N (2s)-2-amino-4-methylpentanoic acid;(2s)-2-aminopropanoic acid Chemical compound C[C@H](N)C(O)=O.CC(C)C[C@H](N)C(O)=O AUXMWYRZQPIXCC-KNIFDHDWSA-N 0.000 description 1
JFOWDKWFHZIMTR-RUCXOUQFSA-N (2s)-2-aminopentanedioic acid;(2s)-2,5-diamino-5-oxopentanoic acid Chemical compound OC(=O)[C@@H](N)CCC(N)=O.OC(=O)[C@@H](N)CCC(O)=O JFOWDKWFHZIMTR-RUCXOUQFSA-N 0.000 description 1
QRXMUCSWCMTJGU-UHFFFAOYSA-L (5-bromo-4-chloro-1h-indol-3-yl) phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP([O-])(=O)[O-])=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-L 0.000 description 1
LJTZPXOCBZRFBH-CIUDSAMLSA-N Ala-Ala-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)N LJTZPXOCBZRFBH-CIUDSAMLSA-N 0.000 description 1
PIPTUBPKYFRLCP-NHCYSSNCSA-N Ala-Ala-Phe Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 PIPTUBPKYFRLCP-NHCYSSNCSA-N 0.000 description 1
YYSWCHMLFJLLBJ-ZLUOBGJFSA-N Ala-Ala-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YYSWCHMLFJLLBJ-ZLUOBGJFSA-N 0.000 description 1
XYTNPQNAZREREP-XQXXSGGOSA-N Ala-Glu-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XYTNPQNAZREREP-XQXXSGGOSA-N 0.000 description 1
IHMCQESUJVZTKW-UBHSHLNASA-N Ala-Phe-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](C)N)CC1=CC=CC=C1 IHMCQESUJVZTKW-UBHSHLNASA-N 0.000 description 1
YYAVDNKUWLAFCV-ACZMJKKPSA-N Ala-Ser-Gln Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(O)=O YYAVDNKUWLAFCV-ACZMJKKPSA-N 0.000 description 1
SAHQGRZIQVEJPF-JXUBOQSCSA-N Ala-Thr-Lys Chemical compound C[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@H](C(O)=O)CCCCN SAHQGRZIQVEJPF-JXUBOQSCSA-N 0.000 description 1
XKHLBBQNPSOGPI-GUBZILKMSA-N Ala-Val-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)N XKHLBBQNPSOGPI-GUBZILKMSA-N 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
SVFOIXMRMLROHO-SRVKXCTJSA-N Asp-Asp-Phe Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SVFOIXMRMLROHO-SRVKXCTJSA-N 0.000 description 1
BSWHERGFUNMWGS-UHFFFAOYSA-N Asp-Ile Chemical compound CCC(C)C(C(O)=O)NC(=O)C(N)CC(O)=O BSWHERGFUNMWGS-UHFFFAOYSA-N 0.000 description 1
GYWQGGUCMDCUJE-DLOVCJGASA-N Asp-Phe-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C)C(O)=O GYWQGGUCMDCUJE-DLOVCJGASA-N 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
102100029516 Basic salivary proline-rich protein 1 Human genes 0.000 description 1
241000252233 Cyprinus carpio Species 0.000 description 1
OABOXRPGTFRBFZ-IMJSIDKUSA-N Cys-Cys Chemical compound SC[C@H](N)C(=O)N[C@@H](CS)C(O)=O OABOXRPGTFRBFZ-IMJSIDKUSA-N 0.000 description 1
OZHXXYOHPLLLMI-CIUDSAMLSA-N Cys-Lys-Ala Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O OZHXXYOHPLLLMI-CIUDSAMLSA-N 0.000 description 1
SAEVTQWAYDPXMU-KATARQTJSA-N Cys-Thr-Leu Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O SAEVTQWAYDPXMU-KATARQTJSA-N 0.000 description 1
VVNCNSJFMMFHPL-VKHMYHEASA-N D-penicillamine Chemical compound CC(C)(S)[C@@H](N)C(O)=O VVNCNSJFMMFHPL-VKHMYHEASA-N 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000008946 Fibrinogen Human genes 0.000 description 1
108010049003 Fibrinogen Proteins 0.000 description 1
YJIUYQKQBBQYHZ-ACZMJKKPSA-N Gln-Ala-Ala Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O YJIUYQKQBBQYHZ-ACZMJKKPSA-N 0.000 description 1
MTCXQQINVAFZKW-MNXVOIDGSA-N Gln-Ile-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)N)N MTCXQQINVAFZKW-MNXVOIDGSA-N 0.000 description 1
206010018364 Glomerulonephritis Diseases 0.000 description 1
RCCDHXSRMWCOOY-GUBZILKMSA-N Glu-Arg-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(O)=O RCCDHXSRMWCOOY-GUBZILKMSA-N 0.000 description 1
OHWJUIXZHVIXJJ-GUBZILKMSA-N Glu-Lys-Cys Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CCC(=O)O)N OHWJUIXZHVIXJJ-GUBZILKMSA-N 0.000 description 1
UERORLSAFUHDGU-AVGNSLFASA-N Glu-Phe-Asn Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCC(=O)O)N UERORLSAFUHDGU-AVGNSLFASA-N 0.000 description 1
KKBWDNZXYLGJEY-UHFFFAOYSA-N Gly-Arg-Pro Natural products NCC(=O)NC(CCNC(=N)N)C(=O)N1CCCC1C(=O)O KKBWDNZXYLGJEY-UHFFFAOYSA-N 0.000 description 1
HQRHFUYMGCHHJS-LURJTMIESA-N Gly-Gly-Arg Chemical compound NCC(=O)NCC(=O)N[C@H](C(O)=O)CCCN=C(N)N HQRHFUYMGCHHJS-LURJTMIESA-N 0.000 description 1
DGKBSGNCMCLDSL-BYULHYEWSA-N Gly-Ile-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)CN DGKBSGNCMCLDSL-BYULHYEWSA-N 0.000 description 1
LRQXRHGQEVWGPV-NHCYSSNCSA-N Gly-Leu-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)CN LRQXRHGQEVWGPV-NHCYSSNCSA-N 0.000 description 1
FXLVSYVJDPCIHH-STQMWFEESA-N Gly-Phe-Arg Chemical compound [H]NCC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O FXLVSYVJDPCIHH-STQMWFEESA-N 0.000 description 1
206010019617 Henoch-Schonlein purpura Diseases 0.000 description 1
FRJIAZKQGSCKPQ-FSPLSTOPSA-N His-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CN=CN1 FRJIAZKQGSCKPQ-FSPLSTOPSA-N 0.000 description 1
KZTLOHBDLMIFSH-XVYDVKMFSA-N His-Ala-Asp Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(O)=O KZTLOHBDLMIFSH-XVYDVKMFSA-N 0.000 description 1
IDNNYVGVSZMQTK-IHRRRGAJSA-N His-Arg-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)N IDNNYVGVSZMQTK-IHRRRGAJSA-N 0.000 description 1
TTYKEFZRLKQTHH-MELADBBJSA-N His-Lys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CC2=CN=CN2)N)C(=O)O TTYKEFZRLKQTHH-MELADBBJSA-N 0.000 description 1
101001125486 Homo sapiens Basic salivary proline-rich protein 1 Proteins 0.000 description 1
101001068639 Homo sapiens Basic salivary proline-rich protein 2 Proteins 0.000 description 1
108010001336 Horseradish Peroxidase Proteins 0.000 description 1
208000031814 IgA Vasculitis Diseases 0.000 description 1
VQUCKIAECLVLAD-SVSWQMSJSA-N Ile-Cys-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N VQUCKIAECLVLAD-SVSWQMSJSA-N 0.000 description 1
GVNNAHIRSDRIII-AJNGGQMLSA-N Ile-Lys-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)O)N GVNNAHIRSDRIII-AJNGGQMLSA-N 0.000 description 1
206010062016 Immunosuppression Diseases 0.000 description 1
241000712431 Influenza A virus Species 0.000 description 1
PMGDADKJMCOXHX-UHFFFAOYSA-N L-Arginyl-L-glutamin-acetat Natural products NC(=N)NCCCC(N)C(=O)NC(CCC(N)=O)C(O)=O PMGDADKJMCOXHX-UHFFFAOYSA-N 0.000 description 1
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
HHSJMSCOLJVTCX-ZDLURKLDSA-N L-Glutaminyl-L-threonine Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H](N)CCC(N)=O HHSJMSCOLJVTCX-ZDLURKLDSA-N 0.000 description 1
QOOWRKBDDXQRHC-BQBZGAKWSA-N L-lysyl-L-alanine Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CCCCN QOOWRKBDDXQRHC-BQBZGAKWSA-N 0.000 description 1
108090001090 Lectins Proteins 0.000 description 1
102000004856 Lectins Human genes 0.000 description 1
HYIFFZAQXPUEAU-QWRGUYRKSA-N Leu-Gly-Leu Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC(C)C HYIFFZAQXPUEAU-QWRGUYRKSA-N 0.000 description 1
OTXBNHIUIHNGAO-UWVGGRQHSA-N Leu-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN OTXBNHIUIHNGAO-UWVGGRQHSA-N 0.000 description 1
ZRHDPZAAWLXXIR-SRVKXCTJSA-N Leu-Lys-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O ZRHDPZAAWLXXIR-SRVKXCTJSA-N 0.000 description 1
JIHDFWWRYHSAQB-GUBZILKMSA-N Leu-Ser-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(O)=O JIHDFWWRYHSAQB-GUBZILKMSA-N 0.000 description 1
AIMGJYMCTAABEN-GVXVVHGQSA-N Leu-Val-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O AIMGJYMCTAABEN-GVXVVHGQSA-N 0.000 description 1
YQFZRHYZLARWDY-IHRRRGAJSA-N Leu-Val-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCCN YQFZRHYZLARWDY-IHRRRGAJSA-N 0.000 description 1
108060001084 Luciferase Proteins 0.000 description 1
239000005089 Luciferase Substances 0.000 description 1
KNKHAVVBVXKOGX-JXUBOQSCSA-N Lys-Ala-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O KNKHAVVBVXKOGX-JXUBOQSCSA-N 0.000 description 1
HEWWNLVEWBJBKA-WDCWCFNPSA-N Lys-Gln-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCCN HEWWNLVEWBJBKA-WDCWCFNPSA-N 0.000 description 1
DRCILAJNUJKAHC-SRVKXCTJSA-N Lys-Glu-Arg Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O DRCILAJNUJKAHC-SRVKXCTJSA-N 0.000 description 1
GRADYHMSAUIKPS-DCAQKATOSA-N Lys-Glu-Gln Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O GRADYHMSAUIKPS-DCAQKATOSA-N 0.000 description 1
ATIPDCIQTUXABX-UWVGGRQHSA-N Lys-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCCN ATIPDCIQTUXABX-UWVGGRQHSA-N 0.000 description 1
LJADEBULDNKJNK-IHRRRGAJSA-N Lys-Leu-Val Chemical compound CC(C)C[C@H](NC(=O)[C@@H](N)CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O LJADEBULDNKJNK-IHRRRGAJSA-N 0.000 description 1
LUTDBHBIHHREDC-IHRRRGAJSA-N Lys-Pro-Lys Chemical compound NCCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(O)=O LUTDBHBIHHREDC-IHRRRGAJSA-N 0.000 description 1
101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 1
XZFYRXDAULDNFX-UHFFFAOYSA-N N-L-cysteinyl-L-phenylalanine Natural products SCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XZFYRXDAULDNFX-UHFFFAOYSA-N 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
102100026594 Olfactory receptor 8B4 Human genes 0.000 description 1
101710143052 Olfactory receptor 8B4 Proteins 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
108010079855 Peptide Aptamers Proteins 0.000 description 1
VJLJGKQAOQJXJG-CIUDSAMLSA-N Pro-Asp-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O VJLJGKQAOQJXJG-CIUDSAMLSA-N 0.000 description 1
GOMUXSCOIWIJFP-GUBZILKMSA-N Pro-Ser-Arg Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O GOMUXSCOIWIJFP-GUBZILKMSA-N 0.000 description 1
LNICFEXCAHIJOR-DCAQKATOSA-N Pro-Ser-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O LNICFEXCAHIJOR-DCAQKATOSA-N 0.000 description 1
239000004365 Protease Substances 0.000 description 1
108010029485 Protein Isoforms Proteins 0.000 description 1
102000001708 Protein Isoforms Human genes 0.000 description 1
206010037549 Purpura Diseases 0.000 description 1
241001672981 Purpura Species 0.000 description 1
206010062237 Renal impairment Diseases 0.000 description 1
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
QKQDTEYDEIJPNK-GUBZILKMSA-N Ser-Glu-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CO QKQDTEYDEIJPNK-GUBZILKMSA-N 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
FLPZMPOZGYPBEN-PPCPHDFISA-N Thr-Leu-Ile Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O FLPZMPOZGYPBEN-PPCPHDFISA-N 0.000 description 1
WCRFXRIWBFRZBR-GGVZMXCHSA-N Thr-Tyr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 WCRFXRIWBFRZBR-GGVZMXCHSA-N 0.000 description 1
HSRXSKHRSXRCFC-WDSKDSINSA-N Val-Ala Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C)C(O)=O HSRXSKHRSXRCFC-WDSKDSINSA-N 0.000 description 1
ROLGIBMFNMZANA-GVXVVHGQSA-N Val-Glu-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)N ROLGIBMFNMZANA-GVXVVHGQSA-N 0.000 description 1
ZXAGTABZUOMUDO-GVXVVHGQSA-N Val-Glu-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O)N ZXAGTABZUOMUDO-GVXVVHGQSA-N 0.000 description 1
MLADEWAIYAPAAU-IHRRRGAJSA-N Val-Lys-His Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N MLADEWAIYAPAAU-IHRRRGAJSA-N 0.000 description 1
OJOMXGVLFKYDKP-QXEWZRGKSA-N Val-Met-Asp Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)O)C(=O)O)N OJOMXGVLFKYDKP-QXEWZRGKSA-N 0.000 description 1
BGXVHVMJZCSOCA-AVGNSLFASA-N Val-Pro-Lys Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)O)N BGXVHVMJZCSOCA-AVGNSLFASA-N 0.000 description 1
SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
HJCUTNIGJHJGCF-UHFFFAOYSA-N acridan acid Natural products C1=CC=C2CC3=CC=CC=C3NC2=C1 HJCUTNIGJHJGCF-UHFFFAOYSA-N 0.000 description 1
108010041407 alanylaspartic acid Proteins 0.000 description 1
230000029936 alkylation Effects 0.000 description 1
238000005804 alkylation reaction Methods 0.000 description 1
KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 1
230000004075 alteration Effects 0.000 description 1
239000000427 antigen Substances 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108010008355 arginyl-glutamine Proteins 0.000 description 1
108010029539 arginyl-prolyl-proline Proteins 0.000 description 1
108010077245 asparaginyl-proline Proteins 0.000 description 1
108010040443 aspartyl-aspartic acid Proteins 0.000 description 1
239000011324 bead Substances 0.000 description 1
102000005936 beta-Galactosidase Human genes 0.000 description 1
108010005774 beta-Galactosidase Proteins 0.000 description 1
239000000090 biomarker Substances 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
210000002665 bowman capsule Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
238000004422 calculation algorithm Methods 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
239000012876 carrier material Substances 0.000 description 1
238000005277 cation exchange chromatography Methods 0.000 description 1
238000000423 cell based assay Methods 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
230000008859 change Effects 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
125000003636 chemical group Chemical group 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
239000012468 concentrated sample Substances 0.000 description 1
238000011109 contamination Methods 0.000 description 1
238000007405 data analysis Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
239000000975 dye Substances 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
230000005684 electric field Effects 0.000 description 1
238000001378 electrochemiluminescence detection Methods 0.000 description 1
238000010828 elution Methods 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
238000007824 enzymatic assay Methods 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
229940012952 fibrinogen Drugs 0.000 description 1
238000001914 filtration Methods 0.000 description 1
238000005206 flow analysis Methods 0.000 description 1
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
108091006047 fluorescent proteins Proteins 0.000 description 1
102000034287 fluorescent proteins Human genes 0.000 description 1
239000005350 fused silica glass Substances 0.000 description 1
231100000853 glomerular lesion Toxicity 0.000 description 1
108010062266 glycyl-glycyl-argininal Proteins 0.000 description 1
229940076085 gold Drugs 0.000 description 1
208000035474 group of disease Diseases 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
108010040030 histidinoalanine Proteins 0.000 description 1
108010092114 histidylphenylalanine Proteins 0.000 description 1
108010085325 histidylproline Proteins 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
208000015446 immunoglobulin a vasculitis Diseases 0.000 description 1
238000001114 immunoprecipitation Methods 0.000 description 1
230000001506 immunosuppresive effect Effects 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
230000002427 irreversible effect Effects 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
238000011862 kidney biopsy Methods 0.000 description 1
230000005977 kidney dysfunction Effects 0.000 description 1
230000003907 kidney function Effects 0.000 description 1
229910052747 lanthanoid Inorganic materials 0.000 description 1
239000002523 lectin Substances 0.000 description 1
108010034529 leucyl-lysine Proteins 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
238000004811 liquid chromatography Methods 0.000 description 1
HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
108010054155 lysyllysine Proteins 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
238000000691 measurement method Methods 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
229910021645 metal ion Inorganic materials 0.000 description 1
238000002493 microarray Methods 0.000 description 1
239000000203 mixture Substances 0.000 description 1
210000000885 nephron Anatomy 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
108091008104 nucleic acid aptamers Proteins 0.000 description 1
239000002777 nucleoside Substances 0.000 description 1
125000003835 nucleoside group Chemical group 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
229940012843 omega-3 fatty acid Drugs 0.000 description 1
235000020660 omega-3 fatty acid Nutrition 0.000 description 1
239000006014 omega-3 oil Substances 0.000 description 1
230000005298 paramagnetic effect Effects 0.000 description 1
239000002245 particle Substances 0.000 description 1
229960001639 penicillamine Drugs 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
230000004481 post-translational protein modification Effects 0.000 description 1
229960005205 prednisolone Drugs 0.000 description 1
OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
239000000047 product Substances 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
238000001243 protein synthesis Methods 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
238000000575 proteomic method Methods 0.000 description 1
238000000746 purification Methods 0.000 description 1
238000013139 quantization Methods 0.000 description 1
239000002096 quantum dot Substances 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
238000011160 research Methods 0.000 description 1
238000004007 reversed phase HPLC Methods 0.000 description 1
238000012552 review Methods 0.000 description 1
239000012146 running buffer Substances 0.000 description 1
229910052707 ruthenium Inorganic materials 0.000 description 1
241000894007 species Species 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
238000004611 spectroscopical analysis Methods 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
238000000756 surface-enhanced laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
238000004885 tandem mass spectrometry Methods 0.000 description 1
MUUHXGOJWVMBDY-UHFFFAOYSA-L tetrazolium blue Chemical compound [Cl-].[Cl-].COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC=CC=2)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 MUUHXGOJWVMBDY-UHFFFAOYSA-L 0.000 description 1
MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
239000012815 thermoplastic material Substances 0.000 description 1
230000008719 thickening Effects 0.000 description 1
108010031491 threonyl-lysyl-glutamic acid Proteins 0.000 description 1
230000014616 translation Effects 0.000 description 1
238000005199 ultracentrifugation Methods 0.000 description 1
238000005353 urine analysis Methods 0.000 description 1
238000010200 validation analysis Methods 0.000 description 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/34—Genitourinary disorders
- G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy

Landscapes

Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Chemical & Material Sciences (AREA)
Urology & Nephrology (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicinal Chemistry (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Food Science & Technology (AREA)
Cell Biology (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Investigating Or Analysing Biological Materials (AREA)
Other Investigation Or Analysis Of Materials By Electrical Means (AREA)

CA 2473814 2004-07-13 2004-07-13 Methode et marqueurs de diagnostic des maladies renales Abandoned CA2473814A1 (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA 2473814 CA2473814A1 (fr)	2004-07-13	2004-07-13	Methode et marqueurs de diagnostic des maladies renales

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CA 2473814 CA2473814A1 (fr)	2004-07-13	2004-07-13	Methode et marqueurs de diagnostic des maladies renales

Publications (1)

Publication Number	Publication Date
CA2473814A1 true CA2473814A1 (fr)	2006-01-13

Family

ID=35610390

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA 2473814 Abandoned CA2473814A1 (fr)	2004-07-13	2004-07-13	Methode et marqueurs de diagnostic des maladies renales

Country Status (1)

Country	Link
CA (1)	CA2473814A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2007063090A1 (fr) *	2005-11-30	2007-06-07	Mosaiques Diagnostics And Therapeutics Ag	Marqueur polypeptidique pour diagnostiquer et evaluer la stenose du meat de l'uretre
EP1972940A1 (fr) *	2007-03-14	2008-09-24	mosaiques diagnostics and therapeutics AG	Procédé et marqueur destinés à diagnostiquer des maladies des reins
WO2023061241A1 (fr) *	2021-10-14	2023-04-20	深圳市陆为生物技术有限公司	Marqueur de diagnostic de lymphocytes t pour une néphropathie d'immunoglobuline a

2004
- 2004-07-13 CA CA 2473814 patent/CA2473814A1/fr not_active Abandoned

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2007063090A1 (fr) *	2005-11-30	2007-06-07	Mosaiques Diagnostics And Therapeutics Ag	Marqueur polypeptidique pour diagnostiquer et evaluer la stenose du meat de l'uretre
EP1972940A1 (fr) *	2007-03-14	2008-09-24	mosaiques diagnostics and therapeutics AG	Procédé et marqueur destinés à diagnostiquer des maladies des reins
WO2008110593A3 (fr) *	2007-03-14	2008-11-13	Mosaiques Diagnostics & Therap	Procédé et marqueurs pour le diagnostic de maladies rénales
JP2010521000A (ja) *	2007-03-14	2010-06-17	モザイクヴェスディアグノシュティクスアンドテラポイティクスアクチェンゲゼルシャフト	腎疾患の診断のための方法およびマーカー
WO2023061241A1 (fr) *	2021-10-14	2023-04-20	深圳市陆为生物技术有限公司	Marqueur de diagnostic de lymphocytes t pour une néphropathie d'immunoglobuline a

Legal Events

Date	Code	Title	Description
2009-06-09	EEER	Examination request
2016-08-24	FZDE	Dead	Effective date: 20160713

Publication	Publication Date	Title
US8389222B2 (en)	2013-03-05	Apolipoprotein fingerprinting technique and methods related thereto
AU2006336091B2 (en)	2013-08-22	Method and markers for the diagnosis of renal diseases
EP3232198A1 (fr)	2017-10-18	Biomarqueur pour le diagnostic de l'hépatome et son utilisation
JP2011501133A (ja)	2011-01-06	心血管または脳血管主要有害事象を検出するための方法
US7297556B2 (en)	2007-11-20	Method of diagnosing nephrotic syndrome
JP2005510575A (ja)	2005-04-21	アルツハイマー病を予測するｉｇ重鎖、ｉｇカッパ、ｉｇラムダバイオポリマーマーカー
US20060286602A1 (en)	2006-12-21	Method and markers for the diagnosis of renal diseases
Pinet et al.	2008	Predicting left ventricular remodeling after a first myocardial infarction by plasma proteome analysis
KR101390543B1 (ko)	2014-04-30	췌장암 진단용 마커 및 이의 용도
JP2009500641A (ja)	2009-01-08	多発性硬化症の診断方法
CA2477035A1 (fr)	2003-09-04	Biomarqueurs de proteines distinguant le cancer de la prostate de cellules non malignes
EP1718763B1 (fr)	2011-09-21	Biomarqueurs seriques de la maladie de chagas
CA2473814A1 (fr)	2006-01-13	Methode et marqueurs de diagnostic des maladies renales
JP2005510721A (ja)	2005-04-21	アルツハイマー病を予測するｉｇラムダバイオポリマーマーカー
KR102131860B1 (ko)	2020-07-08	아르기닌이 메틸화된 ggt1에 특이적으로 결합하는 대장암 진단용 바이오마커 조성물
JP2005510731A (ja)	2005-04-21	Ｉｉ型糖尿病のスクリーニングのためのフィブリノゲンバイオポリマーマーカーおよびその使用
JP2005510718A (ja)	2005-04-21	Ｉｉ型糖尿病を予測する補体ｃ３前駆体バイオポリマーマーカー
KR20080091234A (ko)	2008-10-09	신장 질환의 진단 방법 및 이를 위한 마커
CA2525740A1 (fr)	2004-11-25	Biomarqueurs permettant d'effectuer un diagnostic differentiel de la pancreatite et du cancer du pancreas
JP2005523420A (ja)	2005-08-04	アルツハイマー病を示す補体ｃ３前駆体バイオポリマーマーカー
US20060105367A1 (en)	2006-05-18	Method and markers for the diagnosis of Graft versus Host Disease (GvHD)
JP2005523419A (ja)	2005-08-04	インスリン耐性を示すフィブロネクチンおよびフィブリノゲンバイオポリマーマーカー
JP2005525535A (ja)	2005-08-25	インスリン耐性を示すマクログロブリンバイオポリマーマーカー
KR101819939B1 (ko)	2018-01-19	유방암 진단용 단백질 마커 베타-투 마이크로글로불린 및 이를 검출하는 방법
CN114137225A (zh)	2022-03-04	一种原发性抑郁症的血清多肽诊断分子组合物及其应用